Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Wednesday that it has expanded Vaccine Track, its public data platform developed with IQVIA, to include metro-level vaccination data across 387 US areas and a full decade of insights. The update enables detailed analysis of month-by-month adult immunization trends, supporting local public health decision-making and targeting of vaccination efforts.

Vaccine Track, launched in 2022, remains the only publicly accessible tool offering granular immunization data, now enhanced with quarterly updates. Latest Q1 2025 data show significant variation in vaccination trends between metro areas, with roughly one in five experiencing declines compared to Q1 2024, highlighting opportunities for targeted interventions.

Vaccination gaps contribute to substantial health and economic burdens, costing the US up to USD9bn annually. Less than 25% of US adults were fully up to date on recommended vaccines in 2022, according to CDC data. Vaccine Track aims to address this challenge by equipping public health stakeholders with transparent, actionable data to improve adult vaccination rates.

GSK's Vaccine Track offers interactive dashboards to explore vaccination trends by geography, vaccine type, demographics, payers and points of access. The platform invites public and private sector collaboration through data integration agreements to expand insights and impact.